Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Epidemiology
Published in: European Journal of Epidemiology 9/2009

Open Access 01-09-2009 | CHRONIC DISEASES

The Rotterdam Study: 2010 objectives and design update

Authors: Albert Hofman, Monique M. B. Breteler, Cornelia M. van Duijn, Harry L. A. Janssen, Gabriel P. Krestin, Ernst J. Kuipers, Bruno H. Ch. Stricker, Henning Tiemeier, André G. Uitterlinden, Johannes R. Vingerling, Jacqueline C. M. Witteman

Published in: European Journal of Epidemiology | Issue 9/2009

Login to get access

Abstract

The Rotterdam Study is a prospective cohort study ongoing since 1990 in the city of Rotterdam in The Netherlands. The study targets cardiovascular, endocrine, hepatic, neurological, ophthalmic, psychiatric and respiratory diseases. As of 2008, 14,926 subjects aged 45 years or over comprise the Rotterdam Study cohort. The findings of the Rotterdam Study have been presented in close to a 1,000 research articles and reports (see www.​epib.​nl/​rotterdamstudy). This article gives the rationale of the study and its design. It also presents a summary of the major findings and an update of the objectives and methods.
Literature
1.
2.
Peto R, Doll R. There is no such thing as aging. BMJ. 1997;315:1030–2.PubMed
3.
Hofman A, Grobbee DE, de Jong PTVM, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Study. Eur J Epidemiol. 1991;7:403–22.PubMedCrossRef
4.
Hofman A, Breteler MMB, van Duijn CM, et al. The Rotterdam Study: objectives and design update. Eur J Epidemiol. 2007;22(11):819–29.PubMedCrossRef
5.
Stang A. Appropriate epidemiologic methods as a prerequisite for valid study results. Eur J Epidemiol. 2008;23(12):761–5.PubMedCrossRef
6.
Drame M, Novella JL, Lang PO, et al. Derivation and validation of a mortality-risk index from a cohort of frail elderly patients hospitalised in medical wards via emergencies: the SAFES study. Eur J Epidemiol. 2008;23(12):783–91.PubMedCrossRef
7.
Jaddoe VWV, van Duijn CM, van der Heijden AJ, et al. The Generation R Study: design and cohort update until the age of 4 years. Eur J Epidemiol. 2008;23(12):801–11.PubMedCrossRef
8.
Jacobsen R, Oksuzyan A, Engberg H, et al. Sex differential in mortality trends of old-aged Danes: a nation wide study of age, period and cohort effects. Eur J Epidemiol. 2008;23(11):723–30.PubMedCrossRef
9.
Pekkanen J, Sunyer J. Problems in using incidence to analyze risk factors in follow-up studies. Eur J Epidemiol. 2008;23(9):581–4.PubMedCrossRef
10.
Danesh J, Hingorani A, Wensley F, et al. Collaborative pooled analysis of data on C-reactive protein gene variants and coronary disease: judging causality by Mendelian randomisation. Eur J Epidemiol. 2008;23(8):531–40.CrossRef
11.
Goodman A, Gatward R. Who are we missing? Area deprivation and survey participation. Eur J Epidemiol. 2008;23(6):397–487.CrossRef
12.
Matthiessen J, Biltoft-Jensen A, Rasmussen LB, et al. Comparison of the Danish physical activity questionnaire with a validated position and motion instrument. Eur J Epidemiol. 2008;23(5):311–22.PubMedCrossRef
13.
Larrieu S, Carcaillon L, Lefranc A, et al. Factors associated with morbidity during the 2003 heat wave in two population-based cohorts of elderly subjects: PAQUID and three city. Eur J Epidemiol. 2008;23(4):295–302.PubMedCrossRef
14.
Graff-Iversen S, Anderssen SA, Holme IM, et al. Two short questionnaires on leisure-time physical activity compared with serum lipids, anthropometric measurements and aerobic power in a suburban population from Oslo, Norway. Eur J Epidemiol. 2008;23(3):167–74.PubMedCrossRef
15.
Stolk RP, Rosmalen JGM, Postma DS, et al. Universal risk factors for multifactorial diseases—lifelines: a three-generation population-based study. Eur J Epidemiol. 2008;23(1):67–74.PubMedCrossRef
16.
Menotti A, Lanti M, Kromhout D, et al. Forty-year coronary mortality trends and changes in major risk factors in the first 10 years of follow-up in the seven countries study. Eur J Epidemiol. 2007;22(11):747–54.PubMedCrossRef
17.
Koek HL, Kardaun JWPF, Gevers E, et al. Acute myocardial infarction incidence and hospital mortality: routinely collected national data versus linkage of national registers. Eur J Epidemiol. 2007;22(11):755–62.PubMedCrossRef
18.
Porta M, Pumarega J, Ferrer-Armengou O, et al. Timing of blood extraction in epidemiologic and proteomic studies: results and proposals from the PANKRAS II Study. Eur J Epidemiol. 2007;22(9):577–88.PubMedCrossRef
19.
Thelle DS. Assessment of physical activity and energy expenditure in epidemiological studies. Eur J Epidemiol. 2007;22(6):351–2.PubMedCrossRef
20.
Orsini N, Bellocco R, Bottai M, et al. Reproducibility of the past year and historical self-administered total physical activity questionnaire among older women. Eur J Epidemiol. 2007;22(6):363–8.PubMedCrossRef
21.
Aadahl M, Kjaer M, Jorgensen T. Associations between overall physical activity level and cardiovascular risk factors in an adult population. Eur J Epidemiol. 2007;22(6):369–78.PubMedCrossRef
22.
Kurtze N, Rangul V, Hustvedt BE, et al. Reliability and validity of self-reported physical activity in the Nord-Trondelag health study (HUNT 2). Eur J Epidemiol. 2007;22(6):379–87.PubMedCrossRef
23.
Pitrou I, Dauchet L, Bailly L, et al. Mobile phone follow-up of subjects included in a prospective cohort study: unexpected difficulties. Eur J Epidemiol. 2007;22(6):411–2.PubMedCrossRef
24.
Alonso A, de Irala J, Martinez-Gonzalez MA. Representativeness, losses to follow-up and validity in cohort studies. Eur J Epidemiol. 2007;22(7):481–2.PubMedCrossRef
25.
26.
Ekman A, Klint A, Dickman PW, et al. Optimizing the design of web-based questionnaires—experience from a population-based study among 50, 000 women. Eur J Epidemiol. 2007;22(5):293.PubMedCrossRef
27.
Clarisse B, Nikasinovic L, Poinsard R, et al. The Paris prospective birth cohort study: which design and who participates? Eur J Epidemiol. 2007;22(3):203–10.PubMedCrossRef
28.
Kardys I, Deckers JW, Stricker BH, Vletter WB, Hofman A, Witteman JC. Echocardiographic parameters and all-cause mortality: The Rotterdam Study. Int J Cardiol. 2009;133(2):198–204.PubMedCrossRef
29.
Kardys I, Vliegenthart R, Oudkerk M, Hofman A, Witteman JC. The female advantage in cardiovascular disease: do vascular beds contribute equally? Am J Epidemiol. 2007;166(4):403–12.PubMedCrossRef
30.
Mattace-Raso FUS, Sie MPS, van der Cammen TJM, Safar ME, Hofman A, Van Duijn CM, et al. Insertion//deletion gene polymorphism of the angiotensin-converting enzyme and blood pressure changes in older adults. The Rotterdam Study. J Hum Hypertens. 2007;21(9):736–40.PubMedCrossRef
31.
Koller MT, Steyerberg EW, Wolbers M, Stijnen T, Bucher HC, Hunink MG, et al. Validity of the Framingham point scores in the elderly: results from the Rotterdam Study. Am Heart J. 2007;154(1):87–93.PubMedCrossRef
32.
Elias-Smale SE, Kardys I, Oudkerk M, Hofman A, Witteman JC. C-reactive protein is related to extent and progression of coronary and extra-coronary atherosclerosis; results from the Rotterdam Study. Atherosclerosis. 2007;195(2):e195–202.PubMedCrossRef
33.
Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure the Rotterdam Study. Eur Heart J. 2004;25:1614–9.PubMedCrossRef
34.
Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam Study. Eur Heart J. 2006;27:949–53.PubMedCrossRef
35.
Van Vark LC, Kardys I, Bleumink GS, Knetsch AM, Deckers JW, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity and risk of heart failure: The Rotterdam Study. Eur Heart J. 2006;27:2346–52.PubMedCrossRef
36.
Heeringa J, Van der Kuip DA, Hofman H, Kors JA, Van Rooij FJ, Lip GY, et al. Subclinical atherosclerosis and risk of atrial fibrillation: the Rotterdam Study. Arch Intern Med. 2007;167:382–7.PubMedCrossRef
37.
Heeringa J, Kors JA, Hofman A, Van Rooij FJ, Witteman JC. Cigarette smoking and risk of atrial fibrillation: the Rotterdam Study. Am Heart J. 2008;156:1163–9.PubMedCrossRef
38.
Heeringa J, Hoogendoorn EH, Van der Deure WM, Hofman A, Peeters RP, Hop WC, et al. High-normal thyroid function and risk of atrial fibrillation: the Rotterdam Study. Arch Int Med. 2008;168:2219–24.CrossRef
39.
Dehghan A, Kardys I, De Maat MP, Uitterlinden AG, Sijbrands EJ, Bootsma AH, et al. Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes. 2007;56(3):872–8.PubMedCrossRef
40.
Dehghan A, Van Hoek M, Sijbrands EJ, Hofman A, Witteman JC. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care. 2008;31(2):361–2.PubMedCrossRef
41.
Dehghan A, Köttgen A, Yang Q, Hwang SJ, Kao WL, Rivadeneira F, et al. Association of three genetic loci with uric acid concentration and high risk of gout: a genome-wide association study. Lancet. 2008;372(9654):1953–61.PubMedCrossRef
42.
Köttgen A, Glazer NL, Dehghan A, Hwang SJ, Katz R, Li M, et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet. 2009;41:712–7.CrossRef
43.
Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, et al. Genome-wide association study of blood pressure and hypertension. Nat Genet. 2009;41:677–87.CrossRef
44.
Vasan RS, Glazer NL, Felix JF, Lieb W, Wild P, Felix SB, et al. Genetic variants associated with cardiac structure and function: a meta-analysis of genome-wide association data. JAMA. 2009;302(2):168–78.PubMedCrossRef
45.
Van der Meer IM, Bots ML, Hofman A, del Sol AI, van der Kuip DA, Witteman JC. Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation. 2004;109:1089–94.PubMedCrossRef
46.
Vliegenthart R, Oudkerk M, Hofman A, Oei HHS, van Dijck W, van Rooij F, et al. Coronary calcification improves cardiovascular risk prediction in a population of older adults. Circulation. 2005;112:572–7.PubMedCrossRef
47.
Psaty BM, O’Donnell CJ, Gunadson V, Lunetta KL, Folsom AR, Rotter JI, et al. Design of prospective meta-analyses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet. 2009;2:73–80.CrossRefPubMed
48.
Kardys I, De Maat MP, Uitterlinden AG, Hofman A, Witteman JC. C-reactive protein gene haplotypes and risk of coronary heart disease. The Rotterdam Study. Eur Heart J. 2006;27:1331–7.PubMedCrossRef
49.
Orsini N, Bellocco R, Bottai M, et al. Validity of self-reported total physical activity questionnaire among older women. Eur J Epidemiol. 2008;23(10):661–7.PubMedCrossRef
50.
Laszlo KD, Janszky I, Ahnve S. Income and recurrent events after a coronary event in women. Eur J Epidemiol. 2008;23(10):669–80.PubMedCrossRef
51.
Reuser M, Bonneux L, Willekens F. The burden of mortality of obesity at middle and old age is small. A life table analysis of the US Health and Retirement Survey. Eur J Epidemiol. 2008;23(9):601–7.PubMedCrossRef
52.
McFadden E, Luben R, Wareham N, et al. Occupational social class, risk factors and cardiovascular disease incidence in men and women: a prospective study in the European prospective investigation of cancer and nutrition in Norfolk (EPIC-Norfolk) cohort. Eur J Epidemiol. 2008;23(7):449–58.PubMedCrossRef
53.
Hedlund E, Pehrsson K, Lange A, et al. Country of birth and survival after a first myocardial infarction in Stockholm, Sweden. Eur J Epidemiol. 2008;23(5):341–7.PubMedCrossRef
54.
Casiglia E, Schiavon L, Tikhonoff V, et al. Electrocardiographic criteria of left ventricular hypertrophy in general population. Eur J Epidemiol. 2008;23(4):261–71.PubMedCrossRef
55.
Gemes K, Ahnve S, Janszky I. Inflammation a possible link between economical stress and coronary heart disease. Eur J Epidemiol. 2008;23(2):95–103.PubMedCrossRef
56.
Zatonski W, Campos H, Willett W. Rapid declines in coronary heart disease mortality in Eastern Europe are associated with increased consumption of oils rich in alpha-linolenic acid. Eur J Epidemiol. 2008;23(1):3–10.PubMedCrossRef
57.
The Emerging Risk Factors Collaboration. Analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol. 2007;22(12):839–69.CrossRef
58.
Geleijnse JM, Witteman JCM, Stijnen T, et al. Sodium and potassium intake and risk of cardiovascular events and all-cause mortality: the Rotterdam Study. Eur J Epidemiol. 2007;22(11):763–70.PubMedCrossRef
59.
Andriankaja OM, Genco RJ, Dorn J, et al. Periodontal disease and risk of myocardial infarction: the role of gender and smoking. Eur J Epidemiol. 2007;22(10):699–705.PubMedCrossRef
60.
Hyyppa MT, Maki J, Impivaara O, et al. Individual-level measures of social capital as predictors of all-cause and cardiovascular mortality: a population-based prospective study of men and women in Finland. Eur J Epidemiol. 2007;22(9):589–97.PubMedCrossRef
61.
Pischon T, Mohlig M, Hoffmann K, et al. Comparison of relative and attributable risk of myocardial infarction and stroke according to C-reactive protein and low-density lipoprotein cholesterol levels. Eur J Epidemiol. 2007;22(7):429–38.PubMedCrossRef
62.
Sabour S, Rutten A, van der Schouw YT, et al. Inter-scan reproducibility of coronary calcium measurement using multi detector-row computed tomography (MDCT). Eur J Epidemiol. 2007;22(4):235–43.PubMedCrossRef
63.
Kuller LH. Can we learn more about the etiology of cardiovascular disease? Eur J Epidemiol. 2007;22(2):79–81.PubMedCrossRef
64.
Kabir Z, Bennett K, Critchley JA, et al. Can small changes in cardiovascular risk factors predict large future reductions in coronary heart disease mortality in Ireland? Eur J Epidemiol. 2007;22(2):83–9.PubMedCrossRef
65.
Danesh J, Saracci R, Berglund G, et al. EPIC-heart: the cardiovascular component of a prospective study of nutritional, lifestyle and biological factors in 520, 000 middle-aged participants from 10 European countries. Eur J Epidemiol. 2007;22(2):129–41.PubMedCrossRef
66.
Spencer EA, Pirie KL, Stevens RJ, et al. Diabetes and modifiable risk factors for cardiovascular disease: the prospective Million Women Study. Eur J Epidemiol. 2008;23(12):793–9.PubMedCrossRef
67.
Prugger C, Wellmann J, Heidrich J, et al. Cardiovascular risk factors and mortality in patients with coronary heart disease. Eur J Epidemiol. 2008;23(11):731–7.PubMedCrossRef
68.
Odding E, Valkenburg HA, Stam HJ, Hofman A. Determinants of locomotor disability in people aged 55 years and over: the Rotterdam Study. Eur J Epidemiol. 2001;17(11):1033–41.PubMedCrossRef
69.
Tas U, Verhagen AP, Bierma-Zeinstra SM, Hofman A, Odding E, Pols HA, et al. Incidence and risk factors of disability in the elderly: the Rotterdam Study. Prev Med. 2007;44(3):272–8.PubMedCrossRef
70.
Van der Klift M, De Laet CE, McCloskey EV, Hofman A, Pols HA. The incidence of vertebral fractures in men and women: the Rotterdam Study. J Bone Miner Res. 2002;17(6):1051–6.PubMedCrossRef
71.
Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004;34(1):195–202.PubMedCrossRef
72.
van Daele PL, Burger H, Algra D, Hofman A, Grobbee DE, Birkenhager JC, et al. Age-associated changes in ultrasound measurements of the calcaneus in men and women: the Rotterdam Study. J Bone Miner Res. 1994;9(11):1751–7.PubMedCrossRef
73.
van Daele PL, Seibel MJ, Burger H, Hofman A, Grobbee DE, van Leeuwen JP, et al. Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study. BMJ. 1996;312(7029):482–3.PubMed
74.
Goderie-Plomp HW, van der Klift M, de Ronde W, Hofman A, de Jong FH, Pols HA. Endogenous sex hormones, sex hormone-binding globulin, and the risk of incident vertebral fractures in elderly men and women: the Rotterdam Study. J Clin Endocrinol Metab. 2004;89(7):3261–9.PubMedCrossRef
75.
van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, van der Klift M, de Jonge R, Lindemans J, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med. 2004;350(20):2033–41.PubMedCrossRef
76.
Bergink AP, Uitterlinden AG, Van Leeuwen JP, Hofman A, Verhaar JA, Pols HA. Bone mineral density and vertebral fracture history are associated with incident and progressive radiographic knee osteoarthritis in elderly men and women: the Rotterdam Study. Bone. 2005;37(4):446–56.PubMedCrossRef
77.
van der Klift M, de Laet CE, Coebergh JW, Hofman A, Pols HA. Bone mineral density and the risk of breast cancer: the Rotterdam Study. Bone. 2003;32(3):211–6.PubMedCrossRef
78.
van der Klift M, Pols HA, Hak AE, Witteman JC, Hofman A, de Laet CE. Bone mineral density and the risk of peripheral arterial disease: the Rotterdam Study. Calcif Tissue Int. 2002;70(6):443–9.PubMedCrossRef
79.
van Daele PL, Stolk RP, Burger H, Algra D, Grobbee DE, Hofman A, et al. Bone density in non-insulin-dependent diabetes mellitus. The Rotterdam Study. Ann Intern Med. 1995;122(6):409–14.PubMed
80.
de Liefde II, van der Klift M, de Laet CE, van Daele PL, Hofman A, Pols HA. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int. 2005;16(12):1713–20.PubMedCrossRef
81.
van der Klift M, de Laet CD, Pols HA. Assessment of fracture risk: who should be treated for osteoporosis? Best Pract Res Clin Rheumatol. 2005;19(6):937–50.PubMedCrossRef
82.
de Laet CE, van der Klift M, Hofman A, Pols HA. Osteoporosis in men and women: a story about bone mineral density thresholds and hip fracture risk. J Bone Miner Res. 2002;17(12):2231–6.PubMedCrossRef
83.
De Laet CE, Kanis JA, Oden A, Johanson H, Johnell O, Delmas P, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005;16(11):1330–8.PubMedCrossRef
84.
Reijman M, Hazes JM, Bierma-Zeinstra SM, Koes BW, Christgau S, Christiansen C, et al. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum. 2004;50(8):2471–8.PubMedCrossRef
85.
Reijman M, Hazes JM, Pols HA, Bernsen RM, Koes BW, Bierma-Zeinstra SM. Validity and reliability of three definitions of hip osteoarthritis: cross sectional and longitudinal approach. Ann Rheum Dis. 2004;63(11):1427–33.PubMedCrossRef
86.
Reijman M, Hazes JM, Pols HA, Bernsen RM, Koes BW, Bierma-Zeinstra SM. Role of radiography in predicting progression of osteoarthritis of the hip: prospective cohort study. BMJ. 2005;330(7501):1183.PubMedCrossRef
87.
Brouwer GM, van Tol AW, Bergink AP, Belo JN, Bernsen RM, Reijman M, et al. Association between valgus and varus alignment and the development and progression of radiographic osteoarthritis of the knee. Arthritis Rheum. 2007;56(4):1204–11.PubMedCrossRef
88.
Dahaghin S, Bierma-Zeinstra SM, Reijman M, Pols HA, Hazes JM, Koes BW. Does hand osteoarthritis predict future hip or knee osteoarthritis? Arthritis Rheum. 2005;52(11):3520–7.PubMedCrossRef
89.
Hak AE, Pols HA, Stehouwer CD, Meijer J, Kiliaan JA, Hofman A, et al. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam Study. J Clin Endocrinol Metab. 2001;86(9):4398–405.PubMedCrossRef
90.
Kalmijn S, Mehta KM, Pols HA, Hofman A, Drexhage HA, Breteler MM. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam Study. Clin Endocrinol (Oxf). 2000;53(6):733–7.CrossRef
91.
Smit P, van Schaik RH, van der Werf M, van den Beld AW, Koper JW, Lindemans J, et al. A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels. J Clin Endocrinol Metab. 2005;90(9):5313–6.PubMedCrossRef
92.
Rivadeneira F, van Meurs JB, Kant J, Zillikens MC, Stolk L, Beck TJ, et al. Estrogen receptor beta (ESR2) polymorphisms in interaction with estrogen receptor alpha (ESR1) and insulin-like growth factor I (IGF1) variants influence the risk of fracture in postmenopausal women. J Bone Miner Res. 2006;21(9):1443–56.PubMedCrossRef
93.
Rivadeneira F, Houwing-Duistermaat JJ, Beck TJ, Janssen JA, Hofman A, Pols HA, et al. The influence of an insulin-like growth factor I gene promoter polymorphism on hip bone geometry and the risk of nonvertebral fracture in the elderly: the Rotterdam Study. J Bone Miner Res. 2004;19(8):1280–90.PubMedCrossRef
94.
van Rossum EF, Koper JW, Huizenga NA, Uitterlinden AG, Janssen JA, Brinkmann AO, et al. A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. Diabetes. 2002;51(10):3128–34.PubMedCrossRef
95.
den Heijer T, Schuit SC, Pols HA, van Meurs JB, Hofman A, Koudstaal PJ, et al. Variations in estrogen receptor alpha gene and risk of dementia, and brain volumes on MRI. Mol Psychiatry. 2004;9(12):1129–35.CrossRef
96.
Beck TJ, Ruff CB, Warden KE, Scott WW Jr, Rao GU. Predicting femoral neck strength from bone mineral data. A structural approach. Invest Radiol. 1990;25(1):6–18.PubMedCrossRef
97.
McCloskey EV, Spector TD, Eyres KS, Fern ED, O’Rourke N, Vasikaran S, et al. The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporos Int. 1993;3(3):138–47.PubMedCrossRef
98.
Forsen L, Berntsen GKR, Meyer HE, et al. Differences in precision in bone mineral density measured by SXA and DXA: the NOREPOS study. Eur J Epidemiol. 2008;23(9):615–24.PubMedCrossRef
99.
Ganry O, Lapotre-Ledoux B, Fardellone P, et al. Bone mass density, subsequent risk of colon cancer and survival in postmenopausal women. Eur J Epidemiol. 2008;23(7):467–73.PubMedCrossRef
100.
Yaegashi Y, Onoda T, Tanno K, et al. Association of hip fracture incidence and intake of calcium, magnesium, vitamin D, and vitamin K. Eur J Epidemiol. 2008;23(3):219–25.PubMedCrossRef
101.
Siggeirsdottir K, Aspelund T, Sigurdsson G, et al. Inaccuracy in self-report of fractures may underestimate association with health outcomes when compared with medical record based fracture registry. Eur J Epidemiol. 2007;22(9):631–9.PubMedCrossRef
102.
Yang YJ, Wang YB, Lei SF, et al. AHSG gene polymorphisms are associated with bone mineral density in Caucasian nuclear families. Eur J Epidemiol. 2007;22(8):527–32.PubMedCrossRef
103.
Hong XM, Niu TH, Chen CZ, et al. Familial aggregation of forearm bone mineral density in Chinese. Eur J Epidemiol. 2007;22(5):335–41.PubMedCrossRef
104.
Piirtola M, Vahlberg T, Lopponen M, et al. Fractures as predictors of excess mortality in the aged-A population-based study with a 12-year follow-up. Eur J Epidemiol. 2007;23(11):747–55.CrossRef
105.
Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007;102(12):2708–15.PubMedCrossRef
106.
Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29(12):1705–13.PubMedCrossRef
107.
Talwalkar JA, Kurtz DM, Schoenleber SJ, West CP, Montori VM. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2007;5(10):1214–20.PubMedCrossRef
108.
Ott A, Breteler MMB, van Harskamp F, Claus JJ, van der Cammen TJM, Grobbee DE, et al. Prevalence of Alzheimer’s disease and vascular dementia: association with education. The Rotterdam Study. BMJ. 1995;310:970–3.PubMed
109.
de Rijk MC, Breteler MMB, Graveland GA, Ott A, Grobbee DE, van der Meché FGA, et al. Prevalence of Parkinson’s disease in the elderly. The Rotterdam Study. Neurology. 1995;45:2143–6.PubMed
110.
Ruitenberg A, Ott A, van Swieten JC, Hofman A, Breteler MMB. Incidence of dementia: does gender make a difference? Neurobiol Aging. 2001;22:575–80.PubMedCrossRef
111.
Hollander M, Koudstaal PJ, Bots ML, Grobbee DE, Hofman A, Breteler MMB. Incidence, risk and case fatality of first ever stroke in the elderly population. The Rotterdam Study. J Neurol Neurosurg Psychiatry. 2003;74:317–21.PubMedCrossRef
112.
de Lau LML, Giesbergen PCLM, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MMB. Incidence of parkinsonism and Parkinson’s disease in a general population: The Rotterdam Study. Neurology. 2004;63:1240–4.PubMed
113.
Breteler MMB, Claus JJ, Grobbee DE, Hofman A. Cardiovascular disease and the distribution of cognitive function in an elderly population. The Rotterdam Study. BMJ. 1994;308:1604–8.PubMed
114.
Hofman A, Ott A, Breteler MMB, Bots ML, Slooter AJC, van Harskamp F, et al. Atherosclerosis, apolipoprotein E and the prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet. 1997;349:151–4.PubMedCrossRef
115.
Ott A, Slooter AJC, Hofman A, van Harskamp F, Witteman JCM, van Broeckhoven C, et al. Smoking and risk of dementia and Alzheimer’s disease in a population-based cohort study: the Rotterdam Study. Lancet. 1998;351:1840–3.PubMedCrossRef
116.
Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Hofman A, Witteman JCM, et al. Dietary intake of antioxidants and risk of Alzheimer’s disease: the Rotterdam Study. JAMA. 2002;287:3223–9.PubMedCrossRef
117.
Ruitenberg A, van Swieten JC, Witteman JCM, Mehta KM, van Duijn CM, Hofman A, et al. Alcohol consumption and risk of dementia: the Rotterdam Study. Lancet. 2002;359:281–6.PubMedCrossRef
118.
In ’t Veld BA, Ruitenberg A, Launer LJ, van Duijn CM, Hofman A, Stijnen Th, et al. NSAID and the risk of Alzheimer’s disease or vascular dementia. The Rotterdam Study. New Engl J Med. 2001;345:1515–21.CrossRef
119.
Hollander M, Bots ML, Iglesias del Sol A, Koudstaal PJ, Witteman JCM, Grobbee DE, et al. Carotid plaques increase the risk of stroke and subtypes of cerebral infarction in asymptomatic elderly: The Rotterdam Study. Circulation. 2002;105:2872–7.PubMedCrossRef
120.
Bos MJ, Schipper CMA, Koudstaal PJ, Witteman JCM, Hofman A, Breteler MM. High plasma C-reactive protein level is not an independent predictor for stroke. The Rotterdam Study. Circulation. 2006;114:1591–8.PubMedCrossRef
121.
Vermeer SE, den Heijer T, Prins ND, Hofman A, Koudstaal PJ, Breteler MMB. Silent brain infarcts and the risk of dementia and cognitive decline. The Rotterdam Scan Study. N Engl J Med. 2003;348:1215–22.PubMedCrossRef
122.
Vernooij MW, Ikram MA, Tanghe HL, Vincent AJ, Hofman A, Krestin GP, et al. Incidental findings on brain MRI in the general population. N Engl J Med. 2007;357:1821–8.PubMedCrossRef
123.
Vernooij MW, Ikram MA, Wielopolski PA, Krestin GP, Breteler MMB, van der Lugt A. Cerebral microbleeds: accelerated 3D T2*-weighted GRE MR imaging versus conventional 2D T2*-weighted GRE MR imaging for detection. Radiology. 2008;248:272–7.PubMedCrossRef
124.
Vernooij MW, van der Lugt A, Ikram MA, Wielopolski PA, Hofman A, Krestin GP, et al. Prevalence and risk factors of cerebral microbleeds. The Rotterdam Scan Study. Neurology. 2008;70:1208–14.PubMedCrossRef
125.
Greenberg SM, Vernooij MW, Cordonnier C, Viswanathan A, Al-Shahi Salman R, Warach W, et al. Cerebral microbleeds: A field guide to their detection and interpretation. Lancet Neurol. 2009;8:165–74.PubMedCrossRef
126.
Vernooij MW, De Groot M, Van der Lugt A, Ikram MA, Krestin GP, Hofman A, et al. White matter atrophy and lesion formation explain the loss of structural integrity of white matter in aging. NeuroImage. 2008;43:470–7.PubMedCrossRef
127.
Vernooij MW, Ikram MA, Vrooman HA, Wielopolski PA, Krestin GP, Hofman A, et al. White matter microstructural integrity and cognitive function in a general elderly population. Arch Gen Psych. 2009;66:545–53.CrossRef
128.
Breteler MMB, van Swieten JC, Bots ML, Grobbee DE, Claus JJ, van den Hout JHW, et al. Cerebral white matter lesions, vascular risk factors and cognitive function in a population-based study. Neurology. 1994;44:1246–52.PubMed
129.
de Groot JC, de Leeuw FE, Oudkerk M, Hofman A, Jolles J, Breteler MMB. Cerebral white matter lesions and depressive symptoms in elderly adults. Arch Gen Psychiat. 2000;57:1071–6.PubMedCrossRef
130.
Vingerling JR, Dielemans I, Hofman A, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology. 1995;102:205–10.PubMed
131.
Klaver CC, Wolfs RC, Vingerling JR, Hofman A, de Jong PT. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol. 1998;116:653–8.PubMed
132.
Vingerling JR, Hofman A, Grobbee DE, de Jong PT. Age-related macular degeneration and smoking. The Rotterdam Study. Arch Ophthalmol. 1996;114:1193–6.PubMed
133.
Klaver CC, Assink JJ, Vingerling JR, Hofman A, de Jong PT. Smoking is also associated with age-related macular degeneration in persons aged 85 years and older: The Rotterdam Study. Arch Ophthalmol. 1997;115:945.PubMed
134.
Vingerling JR, Dielemans I, Bots ML, Hofman A, Grobbee DE, de Jong PT. Age-related macular degeneration is associated with atherosclerosis. The Rotterdam Study. Am J Epidemiol. 1995;142:404–9.PubMed
135.
Ikram MK, van Leeuwen R, Vingerling JR, Hofman A, de Jong PT. Relationship between refraction and prevalent as well as incident age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci. 2003;44:3778–82.PubMedCrossRef
136.
Klaver CC, Kliffen M, van Duijn CM, et al. Genetic association of apolipoprotein E with age-related macular degeneration. Am J Hum Genet. 1998;63:200–6.PubMedCrossRef
137.
Klaver CC, Wolfs RC, Assink JJ, van Duijn CM, Hofman A, de Jong PT. Genetic risk of age-related maculopathy. Population-based familial aggregation study. Arch Ophthalmol. 1998;116:1646–51.PubMed
138.
Assink JJ, Klaver CC, Houwing-Duistermaat JJ, et al. Heterogeneity of the genetic risk in age-related macular disease: a population-based familial risk study. Ophthalmology. 2005;112:482–7.PubMedCrossRef
139.
van Leeuwen R, Vingerling JR, de Jong PT. Risk of macular degeneration with statin use should be interpreted with caution. BMJ. 2001;323:1308.PubMedCrossRef
140.
van Leeuwen R, Vingerling JR, Hofman A, de Jong PT, Stricker BH. Cholesterol lowering drugs and risk of age related maculopathy: prospective cohort study with cumulative exposure measurement. BMJ. 2003;326:255–6.PubMedCrossRef
141.
van Leeuwen R, Boekhoorn S, Vingerling JR, et al. Dietary intake of antioxidants and risk of age-related macular degeneration. JAMA. 2005;294:3101–7.PubMedCrossRef
142.
Boekhoorn SS, Vingerling JR, Hofman A, de Jong PT. Alcohol consumption and risk of aging macula disorder in a general population: the Rotterdam Study. Arch Ophthalmol. 2008;126:834–9.PubMedCrossRef
143.
Despriet DD, Klaver CC, Witteman JC, et al. Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA. 2006;296:301–9.PubMedCrossRef
144.
Boekhoorn SS, Vingerling JR, Witteman JC, Hofman A, de Jong PT. C-reactive protein level and risk of aging macula disorder: The Rotterdam Study. Arch Ophthalmol. 2007;125:1396–401.PubMedCrossRef
145.
Boekhoorn SS, Isaacs A, Uitterlinden AG, et al. Polymorphisms in the vascular endothelial growth factor gene and risk of age-related macular degeneration: the Rotterdam Study. Ophthalmology. 2008;115:1899–903.PubMedCrossRef
146.
Ho L, Boekhoorn SS, Liana, et al. Cataract surgery and the risk of aging macula disorder: the Rotterdam Study. Invest Ophthalmol Vis Sci. 2008;49:4795–800.PubMedCrossRef
147.
Ho L, Witteman JC, Rohrer B, Hofman A, de Jong PT, Vingerling JR. Lipoprotein-associated phospholipase A2 and risk of age-related macular degeneration: the Rotterdam Study. Arch Ophthalmol. 2009;127:340–1.PubMedCrossRef
148.
de Voogd S, Ikram MK, Wolfs RC, Jansonius NM, Hofman A, de Jong PT. Incidence of open-angle glaucoma in a general elderly population: the Rotterdam Study. Ophthalmology. 2005;112:1487–93.PubMedCrossRef
149.
Ikram MK, de Jong FJ, Vingerling JR, et al. Are retinal arteriolar or venular diameters associated with markers for cardiovascular disorders? The Rotterdam Study. Invest Ophthalmol Vis Sci. 2004;45:2129–34.PubMedCrossRef
150.
Ikram MK, de Jong FJ, Bos MJ, et al. Retinal vessel diameters and risk of stroke: the Rotterdam Study. Neurology. 2006;66:1339–43.PubMedCrossRef
151.
Ikram MK, De Jong FJ, Van Dijk EJ, et al. Retinal vessel diameters and cerebral small vessel disease: the Rotterdam Scan Study. Brain. 2006;129:182–8.PubMedCrossRef
152.
Ikram MK, Janssen JA, Roos AM, et al. Retinal vessel diameters and risk of impaired fasting glucose or diabetes: the Rotterdam Study. Diabetes. 2006;55:506–10.PubMedCrossRef
153.
Ikram MK, Witteman JC, Vingerling JR, Breteler MM, Hofman A, de Jong PT. Retinal vessel diameters and risk of hypertension: the Rotterdam Study. Hypertension. 2006;47:189–94.PubMedCrossRef
154.
Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol. 1995;39:367–74.PubMedCrossRef
155.
Luijendijk HJ, van den Berg JF, Dekker MJHJ, van Tuijl HR, Otte W, Smit F, et al. Incidence and recurrence of late-life depression. Arch Gen Psychiat. 2008;65:1394–401.PubMedCrossRef
156.
Tiemeier H, van Dijck W, Hofman A, Witteman JCM, Stijnen T, Breteler MMB. Atherosclerosis and late life depression are related. The Rotterdam Study. Arch Gen Psychiat. 2004;61:369–76.PubMedCrossRef
157.
Tiemeier H, van Tuijl HR, Hofman A, Kiliaan AJ, Breteler MMB. Plasma fatty acid composition and depression in the elderly are associated: The Rotterdam Study. Am J Clin Nutr. 2003;78:40–6.PubMed
158.
Naarding P, Tiemeier H, Breteler MM, Schoevers RA, Jonker C, Koudstaal PJ, et al. Clinically defined vascular depression in the general population. Psychol Med. 2007;37:383–92.PubMedCrossRef
159.
van den Berg JF, Knvistingh Neven A, Tulen JH, Hofman A, Witteman JC, Miedema HM, et al. Actigraphic sleep duration and fragmentation are related to obesity in the elderly: the Rotterdam Study. Int J Obes. 2008;32:1083–90.CrossRef
160.
van den Berg JF, Miedema HM, Tulen JH, Neven AK, Hofman A, Witteman JC, et al. Long sleep duration is associated with serum cholesterol in the elderly: the Rotterdam Study. Psychosom Med. 2008;70:1005–11.PubMedCrossRef
161.
Van der Berg JF, Luijendijk HJ, Tulen JH, Hofman A, Neven AK, Tiemeier H. Sleep in depression and anxiety disorders: a population-based study of elderly persons. J Clin Psychiatry. 2009. doi:10.​4088/​JCP.​08m04448
162.
Omidvar M, Stolk L, Uitterlinden AG, Hofman A, Van Duijn CM, Tiemeier H. The effect of catechol-O-methyltransferase Met/Val functional polymorphism on smoking cessation: retrospective and prospective analyses in a cohort study. Pharmacogenet Genomics. 2009;19:45–51.PubMedCrossRef
163.
Tiemeier H, Schuit SC, den Heijer T, van Meurs JB, van Tuijl HR, Hofman A, et al. Estrogen receptor alpha gene polymorphisms and anxiety disorder in an elderly population. Mol Psychiatry. 2005;10:806–7.PubMedCrossRef
164.
Tiemeier H, van Tuijl HR, Hofman A, Meijer J, Kiliaan AJ, Breteler MMB. Vitamin B12, folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry. 2002;159:2099–101.PubMedCrossRef
165.
Tiemeier H, Hofman A, Kiliaan AJ, Meijer J, Breteler MMB. Vitamin E and depressive symptoms are not related. The Rotterdam Study. J Affect Disord. 2002;72:79–83. 162.PubMedCrossRef
166.
Dekker MJ, Koper JW, van Aken MO, Pols HA, Hofman A, de Jong FH, et al. Salivary cortisol is related to atherosclerosis of carotid arteries. J Clin Endocrinol Metab. 2008;93:3741–7.PubMedCrossRef
167.
Ikram MA, Luijendijk HJ, Vernooij MW, Hofman A, Niessen WJ, van der Lugt A, Tiemeier H, Breteler MMB. Structural markers of vascular brain disease in relation to depression in the elderly. Epidemiology (in press).
168.
Bos MJ, Lindén T, Koudstaal PJ, Hofman A, Skoog I, Breteler MMB, et al. Depressive symptoms and risk of stroke: The Rotterdam Study. J Neurol Neurosurg Psychiat. 2008;79:997–1001.PubMedCrossRef
169.
Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R. Scan: schedules for clinical assessment in neuropsychiatry. Arch Gen Psychiatry. 1990;47:589–93.PubMed
170.
Wittchen HU, Lachner G, Wunderlich U, Pfister H. Test–retest reliability of the computerized DSM-IV version of the Munich-composite international diagnostic interview (M-CIDI). Soc Psychiatry Psychiatr Epidemiol. 1998;33:568–78.PubMedCrossRef
171.
van den Berg JF, van Rooij FJ, Vos H, Tulen JH, Hofman A, Miedema HM, et al. Disagreement between subjective and actigraphic measures of sleep duration in a population-based study of elderly persons. J Sleep Res. 2008;17:295–302.CrossRef
172.
Prigerson HG, Maciejewski PK, Reynolds CF III, Bierhals AJ, Newsom JT, Fasiczka A, et al. Inventory of complicated grief: a scale to measure maladaptive symptoms of loss. Psychiatry Res. 1995;59:65–79.PubMedCrossRef
173.
van Durme YM, Verhamme KM, Stijnen T, van Rooij FJ, Van Pottelberge GR, Hofman A, et al. Prevalence, incidence, and lifetime risk for the development of COPD in the elderly: the Rotterdam Study. Chest. 2009;135:368–77.PubMedCrossRef
174.
Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747–57.PubMedCrossRef
175.
van Durme YM, Verhamme KM, Aarnoudse AJ, Van Pottelberge GR, Hofman A, Witteman JC, et al. C-reactive protein levels, haplotypes, and the risk of incident chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179:375–82.PubMedCrossRef
176.
Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26:720–35.PubMedCrossRef
177.
Duijts L, Jaddoe VWV, Hofman A, et al. Maternal smoking in prenatal and early postnatal life and the risk of respiratory tract infections in infancy. The generation R study. Eur J Epidemiol. 2008;23(8):547–55.PubMedCrossRef
178.
Lawlor DA, Cooper AR, Bain C, et al. Associations of birth size and duration of breast feeding with cardiorespiratory fitness in childhood: findings from the Avon longitudinal study of parents and children (ALSPAC). Eur J Epidemiol. 2008;23(6):411–22.PubMedCrossRef
179.
Kompauer I, Demmelmair H, Koletzko B, et al. Association of fatty acids in serum phospholipids with lung function and bronchial hyperresponsiveness in adults. Eur J Epidemiol. 2008;23(3):175–90.PubMedCrossRef
180.
de Luise C, Brimacombe M, Pedersen L, et al. Chronic obstructive pulmonary disease and mortality following hip fracture: a population-based cohort study. Eur J Epidemiol. 2008;23(2):115–22.PubMedCrossRef
181.
Hugg T, Ruotsalainen R, Jaakkola MS, et al. Comparison of allergic diseases, symptoms and respiratory infections between Finnish and Russian school children. Eur J Epidemiol. 2008;23(2):123–33.PubMedCrossRef
182.
Rzehak P, Schoefer Y, Wichmann HE, et al. A prospective study on the association between hay fever among children and incidence of asthma in East Germany. Eur J Epidemiol. 2008;23(1):17–22.PubMedCrossRef
183.
Svartberg J, Schirmer H, Medbo A, et al. Reduced pulmonary function is associated with lower levels of endogenous total and free testosterone. The Tromso Study. Eur J Epidemiol. 2007;22(2):107–12.PubMedCrossRef
184.
Moreno T, Querol X, Alastuey A, et al. Airborne particulate matter and premature deaths in urban Europe: the new WHO guidelines and the challenge ahead as illustrated by Spain—Commentary. Eur J Epidemiol. 2007;22(1):1–5.PubMedCrossRef
185.
van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, van der Klift M, de Jonge R, Lindemans J, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med. 2004;350:2033–41.PubMedCrossRef
186.
Vaessen N, Janssen JA, Heutink P, Hofman A, Lamberts SW, Oostra BA, et al. Association between genetic variation in the gene for insulin-like growth factor-I and low birthweight. Lancet. 2002;359:1036–7.PubMedCrossRef
187.
van Meurs JBJ, Schuit SCE, Weel AEAM, van der Klift M, Bergink AP, Arp PP, et al. Association of 5′ estrogen recptor alpha gene polymorphisms with bone mineral density, vertebral bone area, and fracture risk. Hum Molec Genet. 2003;12:1745–54.PubMedCrossRef
188.
Schuit SC, Oei HH, Witteman JC, Geurts van Kessel CH, van Meurs JB, Nijhuis RL, et al. Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction. JAMA. 2004;291:2969–77.PubMedCrossRef
189.
Ioannidis JP, Gwinn M, Little J, Higgins JP, Bernstein JL, Boffetta P, et al. Human genome epidemiology network and the network of investigator networks. A roadmap for efficient and reliable human genome epidemiology. Nat Genet. 2006;38(1):3–5.PubMedCrossRef
190.
Ioannidis JPA, Ralston SH, Bennett ST, Brandi ML, Grinberg D, Karassa FB, et al. Large-scale evidence for differential genetic effects of ESR1 polymorphisms on osteoporosis outcomes: The GENOMOS Study. JAMA. 2004;292(17):2105–14.PubMedCrossRef
191.
Uitterlinden AG, Ralston SH, Brandi ML, Carey AH, Grinberg D, Langdahl BL, et al. Large-scale analysis of association between common vitamin D receptor gene variations and osteoporosis: the GENOMOS study. Ann Int Medicine. 2006;145(4):255–64.
192.
Aarnoudse AJLHJ, Newton-Cheh C, de Bakker PIW, Straus SMJM, Kors JA, Hofman A, et al. A common NOS1AP variant is associated with longer QTc interval and sudden cardiac death: the Rotterdam Study. Circulation. 2007;116:10–6.PubMedCrossRef
193.
Fang Y, van Meurs JB, d’Alesio A, Jhamai M, Zhao H, Rivadeneira F, et al. Promoter and 3′UTR haplotypes in the vitamin D receptor gene predispose to osteoporotic fracture: the Rotterdam Study. Am J Hum Genet. 2005;77(5):807–23.PubMedCrossRef
194.
Willer CJ, Speliotes EK, Loos RJF, Li S, Lindgren CM, Heid IM, et al. Six new loci associated with body mass index highlight a neural influence on body weight regulation. Nat Genet. 2009;41:25–34.PubMedCrossRef
195.
Prokopenko I, Langenberg C, Florez JC, Saxena R, Soranzo N, Thorleifsson G, et al. Variants in the melatonin receptor 1B gene (MTNR1B) influence fasting glucose levels. Nat Genet. 2009;4191:77–81.CrossRef
196.
Aulchenko YS, Ripatti S, Lindqvist I, Boomsma D, Heid IM, Pramstaller PP, et al. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet. 2009;41:47–55.PubMedCrossRef
197.
Aulchenko YS, Ripke S, Isaacs A, van Duijn CM. GenABEL: an R library for genome-wide association analysis. Bioinformatics. 2007;23(10):1294–6.PubMedCrossRef
198.
Lei L, Ye LN, Liu H, et al. Passive smoking, cytochrome P450 gene polymorphisms and dysmenorrhea. Eur J Epidemiol. 2008;23(7):475–81.PubMedCrossRef
199.
Mao RF, Fan YH, Chen F, et al. Genetic polymorphism of MTHFR G1793A in Chinese populations. Eur J Epidemiol. 2008;23(5):363–8.PubMedCrossRef
200.
Seabra AF, Mendonca DM, Goring HHH, et al. Genetic and environmental factors in familial clustering in physical activity. Eur J Epidemiol. 2008;23(3):205–11.PubMedCrossRef
201.
Porta M, Pumarega J, Ferrer-Armengou O, et al. Timing of blood extraction in epidemiologic and proteomic studies: results and proposals from the PANKRAS II Study. Eur J Epidemiol. 2007;22:577–88.PubMedCrossRef
202.
Jaddoe VWV, Bakker R, van Duijn CM, et al. The Generation R Study Biobank: a resource for epidemiological studies in children and their parents. Eur J Epidemiol. 2007;22(12):917–23.PubMedCrossRef
203.
Isaacs A, Sayed-Tabatabaei FA, Aulchenko YS, et al. Heritabilities, apolipoprotein E, and effects of inbreeding on plasma lipids in a genetically isolated population: The Erasmus Rucphen Family Study. Eur J Epidemiol. 2007;22(2):99–105.PubMedCrossRef
204.
De Moor MHM, Stubbe JH, Boomsma DI, et al. Exercise participation and self-rated health: do common genes explain the association? Eur J Epidemiol. 2007;22(1):27–32.PubMedCrossRef
205.
Janssens ACJW. Is it the time right for translation research in genomics? Eur J Epidemiol. 2008;23(11):707–10.PubMedCrossRef
206.
In ’t Veld BA, Ruitenberg A, Hofman A, Stricker BHCh, Breteler MMB. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging. 2001;22:407–12.CrossRef
207.
Feenstra J, Heerdink ER, Grobbee DE, Stricker BHCh. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure. Arch Int Med. 2002;162:265–70.CrossRef
208.
Straus SM, Kors JA, de Bruin ML, van der Hooft CS, Hofman A, Heeringa J, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol. 2006;47:362–7.PubMedCrossRef
209.
Van der Hooft CS, Heeringa J, Brusselle GG, Hofman A, Witteman JCM, Kingma JH, et al. Corticosteroids and the risk of atrial fibrillation. Arch Int Med. 2006;165:1016–20.CrossRef
210.
Schoofs MWCJ, van der Klift M, Hofman A, de Laet CEDH, Herings RMC, Stijnen Th, et al. Thiazide diuretics and the risk for hip fracture. Ann Intern Med. 2003;139:476–82.PubMed
211.
Schoofs MW, Sturkenboom MCJM, van der Klift M, Hofman A, Pols HA, Stricker BHCh. HMG-CoA reductase inhibitors and the risk of vertebral fracture. J Bone Miner Res. 2004;19:1525–30.PubMedCrossRef
212.
Reijman M, Bierma-Zeinstra SM, Pols HAP, Koes BW, Stricker BHCh, Hazes JM. Is there an association between the use of different types of NSAIDs and radiologic progression of osteoarthritis? The Rotterdam Study. Arthritis Rheum. 2005;52:3137–42.PubMedCrossRef
213.
Visser LE, Penning-van Beest FJA, Kasbergen AAH, De Smet PAGM, Vulto AG, Hofman A, et al. Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants. Clin Pharmacol Ther. 2002;71:496–502.PubMedCrossRef
214.
Visser LE, Penning-van Beest FJA, Kasbergen HAA, De Smet PAGM, Vulto AG, Hofman A, et al. Overanticoagulation associated with combined use of antibacterial agents and acenocoumarol or phenprocoumon anticoagulants. Thromb Haemost. 2002;88:705–10.PubMed
215.
Visser LE, van Vliet M, van Schaik RHN, Kasbergen AAH, de Smet PAGM, Vulto AG, et al. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics. 2004;14:27–33.PubMedCrossRef
216.
Visser LE, Penning-van Beest FJ, Wilson JHP, Vulto AG, Kasbergen AA, de Smet PAGM, et al. Overanticoagulation associated with combined use of lactulose and coumarin anticoagulants. Br J Clin Pharmacol. 2004;57:522–4.PubMedCrossRef
217.
Visser LE, van Schaik RH, van Vliet M, Trienekens PH, de Smet PAGM, Vulto AG, et al. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost. 2004;92:61–6.PubMed
218.
Visser LE, Bleumink GS, Trienekens PH, Vulto AG, Hofman A, Stricker BHCh. The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants. Br J Haematol. 2004;127:85–9.PubMedCrossRef
219.
Visser LE, van Schaik RHN, van Vliet M, Trienekens PH, de Smet PAGM, Vulto AG, et al. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants. Clin Pharmacol Ther. 2005;77:479–85.PubMedCrossRef
220.
Bleumink GS, Schut AF, Sturkenboom MC, van Duijn CM, Deckers JW, Hofman A, et al. Mortality in patients with hypertension on ACE-inhibitor treatment is influenced by the ACE I/D polymorphism. Pharmacogenet Genomics. 2005;15:75–81.PubMedCrossRef
221.
Visser LE, Trienekens PH, de Smet PAGM, Vulto AG, Hofman A, van Duijn CM, et al. Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants. Pharmacogenet Genomics. 2005;15:69–74.PubMedCrossRef
222.
Schelleman H, Klungel OH, Witteman JCM, Hofman A, van Duijn CM, de Boer A, et al. The influence of the alpha-adducin G460W polymorphism and angiotensinogen M235T polymorphism on antihypertensive medication and blood pressure. Eur J Hum Gen. 2006;14:860–6.CrossRef
223.
Schelleman H, Klungel OH, van Duijn CM, Witteman JCM, Hofman A, de Boer A, et al. Drug-gene interaction between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and antihypertensive therapy. Ann Pharmacother. 2006;40:212–8.PubMedCrossRef
224.
Becker ML, Visser LE, Tirnekens PH, Hofman A, van Schaik RH, Stricker BHCh. Cytochrome P450 2C9*2 and *3 polymorphisms and the dose and effect of sulphonylurea in type II diabetes mellitus. Clin Pharmacol Ther. 2008;83:288–92.PubMedCrossRef
225.
Visser LE, van Schaik RH, Danser JAH, Hofman A, Witteman JCM, van Duijn CM, et al. The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9. Pharmacogen Genomics. 2007;17:473–9.CrossRef
226.
Schelleman H, Klungel OH, Witteman JCM, Breteler MMB, Yazdanpanah M, Danser AH, et al. Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers. Eur J Hum Genet. 2007;15:478–84.PubMedCrossRef
227.
Schelleman H, Klungel OH, Witteman JCM, Hofman A, van Duijn CM, de Boer A, et al. Pharmacogenetic interactions of three candidate gene polymorphisms with ACE-inhibitors or beta-blockers and the risk of atherosclerosis. Br J Clin Pharmacol. 2007;64:57–66.PubMedCrossRef
228.
Schelleman H, Klungel OH, Witteman JCM, Breteler MMB, Hofman A, van Duijn CM, et al. Diuretic-gene interaction and the risk of myocardial infarction and stroke. Pharmacogenomics J. 2007;7:346–52.PubMedCrossRef
229.
Aarnoudse AJ, Dieleman JP, Visser LE, Arp PP, van der Heiden IP, van Schaik RH, et al. Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet Genomics. 2008;18:299–305.PubMedCrossRef
230.
Teichert M, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, De Smet PA, et al. Vitamin K epoxide reductase complex subunit 1 (VKORC1) polymorphism and aortic calcification: the Rotterdam Study. Arterioscler Thromb Vasc Biol. 2008;28:771–6.PubMedCrossRef
231.
Bijl MJ, Visser LE, Hofman A, Vulto AG, van Gelder T, Stricker BHCh, et al. Influence of the CYP2D6*4 polymorphism on dose, switching, and discontinuation of antidepressants. Br J Clin Pharmacol. 2008;65:558–64.PubMedCrossRef
232.
Becker ML, Visser LE, Newton-Cheh C, Witteman JC, Hofman A, Uitterlinden AG, et al. Genetic variation in the NOS1AP gene is associated with the incidence of diabetes mellitus in users of calcium channel blockers. Diabetologia. 2008;51:2138–40.PubMedCrossRef
233.
Becker ML, Aarnoudse AJ, Newton-Cheh C, Hofman A, Witteman JC, Uitterlinden AG, et al. Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea. Pharmacogenet Genomics. 2008;18:591–7.PubMed
234.
Bijl M, Visser L, van Schaik R, Kors J, Witteman J, Hofman A, et al. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Clin Pharmacol Ther. 2009;85(1):45–50.PubMedCrossRef
235.
Davis S, Mirick DK. Medication use and the risk of breast cancer. Eur J Epidemiol. 2007;22(5):319–25.PubMedCrossRef
236.
de Luise C, Lanes SF, Jacobsen J, et al. Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark. Eur J Epidemiol. 2007;22(4):267–72.PubMedCrossRef
237.
Gouya G, Reichardt B, Ohrenberger G, et al. Survival of patients discharged after acute myocardial infarction and evidence-based drug therapy. Eur J Epidemiol. 2007;22(3):145–9.PubMedCrossRef
238.
Osterbrand M, Fahlen M, Oden A, et al. A method to predict the metabolic effects of changes in insulin treatment in subgroups of a large population based patient cohort. Eur J Epidemiol. 2007;22(3):151–7.PubMedCrossRef
239.
Hak AE, Pols HAP, Visser TJ, Drexhage HA, Hofman A, Witteman JCM. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med. 2000;132:270–8.PubMed
240.
Uccelli R, Binazzi A, Altavista P, et al. Geographic distribution of amyotrophic lateral sclerosis through motor neuron disease mortality data. Eur J Epidemiol. 2007;22(11):781–90.PubMedCrossRef
241.
Landes M, Thorne M, Barlow P, et al. Prevalence of sexually transmitted infections in HIV-1 infected pregnant women in Europe. Eur J Epidemiol. 2007;22:1925–36.CrossRef
242.
Lang PO, Meyer N, Heitz D, et al. Loss of independence in Katz’s ADL ability in connection with an acute hospitalization: early clinical markers in French older people. Eur J Epidemiol. 2007;22(9):621–30.PubMedCrossRef
Metadata
Title
The Rotterdam Study: 2010 objectives and design update
Authors
Albert Hofman
Monique M. B. Breteler
Cornelia M. van Duijn
Harry L. A. Janssen
Gabriel P. Krestin
Ernst J. Kuipers
Bruno H. Ch. Stricker
Henning Tiemeier
André G. Uitterlinden
Johannes R. Vingerling
Jacqueline C. M. Witteman
Publication date
01-09-2009
Publisher
Springer Netherlands
Published in
European Journal of Epidemiology / Issue 9/2009
Print ISSN: 0393-2990
Electronic ISSN: 1573-7284
DOI
https://doi.org/10.1007/s10654-009-9386-z

Other articles of this Issue 9/2009

European Journal of Epidemiology 9/2009 Go to the issue

DIABETES MELLITUS

Influence of childhood parental history of type 2 diabetes on the pre-diabetic and diabetic status in adulthood: the Bogalusa Heart Study

CANCER

Incidence and prognosis of cholangiocarcinoma in Danish patients with and without inflammatory bowel disease: a national cohort study, 1978–2003

DEVELOPMENTAL EPIDEMIOLOGY

Work as a physician and adverse pregnancy outcomes: a Finnish nationwide population-based registry study

CARDIOVASCULAR DISEASE

The association between birthplace in different regions of the world and cardiovascular mortality among residents of Spain

NEW STUDY

The Mothers and Children’s Environmental Health (MOCEH) study

PEDIATRIC EPIDEMIOLOGY

Sonographic assessment of abdominal fat distribution in infancy